Breast Cancer: Page 6

Lab Genomics, Canexia secure MolDX coverage for DNA assay
By LabPulse.com staff writers
The decision allows for Medicare coverage of Follow It for breast, lung, and colorectal cancers, the two firms said. Follow It can help guide cancer treatment, according to the companies.
November 1, 2021
2021 01 12 23 44 3780 Blood Test Samples Lab 400
Lucence, Yemaachi team up on liquid biopsy study in Africa
By LabPulse.com staff writers
The trial, called The Liquid Biopsy for Detection of Actionable Genomic Mutations in Women of African Descent with Advanced Breast Cancer (AMBER), will prospectively explore the utility of Lucence's LiquidHallmark cell-free DNA (cfDNA) liquid biopsy assay in identifying actionable genetic mutations in metastatic breast cancer patients in Ghana.
October 25, 2021
2019 07 27 00 04 3609 Breast Cancer Cell 400
Agilent receives FDA approval for breast cancer assay
By LabPulse.com staff writers
The assay is intended for use in patients for whom adjuvant treatment with Verzenio (abemaciclib), in combination with endocrine therapy, is being considered. It is the first IHC assay measuring Ki-67 expression to receive FDA approval in conjunction with the treatment of Verzenio and was developed in collaboration with Eli Lilly and Company, Agilent said.
October 13, 2021
2019 12 12 00 55 0189 Breast Cancer3 400
Immunis.AI closes on funding for immunogenomic platform
By LabPulse.com staff writers
The company said the funding will support further validation and commercialization of the company's prostate cancer molecular test and will expand development of new tests in breast, colon, lung cancer, and other cancers.
September 30, 2021
2019 08 05 19 10 8249 Dollar Sign 400
AI improves precision in breast cancer diagnosis
By LabPulse.com staff writers
Researchers at the Karolinska Institutet trained the AI model to recognize characteristics of high-resolution microscopic images from patients classified with grade 1-3 tumors. The study is based on an extensive microscopic image bank of 2,800 tumors.
September 29, 2021
2021 08 18 23 12 2135 Computer Ai Artificial Illustration 400
AI helps discover new prognostic breast cancer biomarker
By LabPulse.com staff writers
The biomarker, specifically collagen, is identified in tissue biopsy samples from women with early-stage breast cancer and can predict if cancer will return after treatment. A team led by doctoral student Haojia Li digitized images of tissue sample slides and discovered that "a well-ordered arrangement of collagen" predicts an aggressive tumor and disease recurrence while "disordered" or "broken-down" collagen predicts better outcomes.
August 8, 2021
2019 04 15 22 17 2307 Breast Cancer 400
Natera's MRD test used in breast cancer drug trial
By LabPulse.com staff writers
Signatera was used to screen the first patient in GlaxoSmithKline's Zest Study. The trial aims to test the efficacy and safety of treatment with the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib after surgery or adjuvant therapy in 800 patients with triple-negative breast cancer or HR-positive/HER2-negative, BRCA-mutated breast cancer.
August 3, 2021
2019 04 15 22 17 2307 Breast Cancer 400
Natera and BGI launch new assay in China
By LabPulse.com staff writers
The Signatera assay was tested in studies in nonsmall cell lung, bladder, breast, and colorectal cancers and identifies MRD up to two years earlier than standard imaging, the companies said in a release.
June 23, 2021
2019 08 12 20 23 3708 Lab Blood Centrifuge 400
Epredia, Aiforia ink distribution agreement
By LabPulse.com staff writers
Epredia will distribute Aiforia's Ki67 AI model, which has the CE-IVD Mark, for breast cancer diagnostics in Denmark, France, Germany, Iceland, Italy, Japan, Norway, Spain, Sweden, and the U.S. The software will be part of Epredia's digital pathology portfolio, which already includes its 3DHistech P1000 WSI scanner, the company said.
June 20, 2021
2021 06 21 19 08 4301 Clinical Ki67 Ia 400
Agendia touts MammaPrint clinical results
By LabPulse.com staff writers
The research demonstrated a higher than 99% eight-year breast cancer-specific survival rate for patients who were characterized as MammaPrint Ultra Low Risk status, no matter their clinical risk, the company said.
June 6, 2021
2019 04 17 00 53 3368 Dna Sequence 400
New biosensor aids early diagnosis of breast cancer
By LabPulse.com staff writers
In a study published in ACS Sensors, a research team led by Dr. Ramón Martínez Máñez from Valencia Polytechnic University noted that mammography is the gold standard for breast cancer detection, but radiation and lower sensitivity and specificity in young women with dense breast tissue are drawbacks to the imaging technology.
May 20, 2021
2021 05 21 20 55 6118 Breast Cancer 3 D 400
Liquid biopsy enhances MRI studies of breast cancer patients
By Emily Hayes
Measuring plasma cell-free DNA (cfDNA) in patients after chemotherapy and prior to surgery has the potential to improve the accuracy of MRI alone in patients treated for localized breast cancer, according to the study, which was reported as a late-breaking presentation and featured in the press program at the virtual meeting.
April 10, 2021
2016 10 05 17 45 45 493 Breast Cancer 400
Previous Page
Page 6 of 12
Next Page